» Articles » PMID: 6234273

Frequency of Appearance of Resistant Variants to Norfloxacin and Nalidixic Acid

Overview
Date 1984 May 1
PMID 6234273
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical use of nalidixic acid has been hampered by the rapid appearance of resistant variants. This study compares the frequency of appearance of resistant variants to nalidixic acid and norfloxacin, a new quinolone-carboxylic acid with superior antimicrobial activity. We found a lower frequency of appearance of resistant variants with norfloxacin, although there was some cross-resistance between the two drugs. A gradation in this frequency was also noted between the species of Gram-negative rods tested, so that larger numbers of resistant variants appeared with the non-fermenters.

Citing Articles

Comparison of norfloxacin versus nalidixic acid in therapy of acute urinary tract infections.

Selin L, Harding G, Thomson M, Kennedy J, Urias B, Ronald A Can J Infect Dis. 2012; 1(2):35-40.

PMID: 22553437 PMC: 3327960. DOI: 10.1155/1990/482960.


The prevention of antibiotic resistance during treatment.

Williams J, Sefton A Infection. 2000; 27 Suppl 2:S29-31.

PMID: 10885824 DOI: 10.1007/BF02561667.


Quo vadis with bacterial resistance?.

Williams J Drugs. 1995; 49 Suppl 2:1-9.

PMID: 8549275 DOI: 10.2165/00003495-199500492-00003.


In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii.

Vila J, Marcos A, Marco F, Abdalla S, Vergara Y, REIG R Antimicrob Agents Chemother. 1993; 37(1):138-41.

PMID: 8431011 PMC: 187622. DOI: 10.1128/AAC.37.1.138.


Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli.

Heisig P, Schedletzky H Antimicrob Agents Chemother. 1993; 37(4):696-701.

PMID: 8388197 PMC: 187737. DOI: 10.1128/AAC.37.4.696.